SALT LAKE CITY, April 28, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize energy to treat cancer, today announced the appointment of Peter Vitulli to the Company's Board of Directors effective April 23, 2015. Mr. Vitulli, President and CEO of DNA Diagnostics Center (DDC), will serve as an independent director to Perseon.
Timothy C. McQuay, Chairman of the Board of Directors of Perseon, commented, "Peter is a versatile leader in healthcare who brings an impressive combination of small- to medium-sized company growth and turnaround expertise to Perseon. His deep understanding of the consumer and peer-to-peer markets and proven ability to drive innovation and brand development will add a rich layer of talent and acumen to our corporate governance."
Mr. Vitulli has over 35 years of experience within the consumer products and healthcare industries in both large corporations and entrepreneurial-stage companies. Prior to joining DDC, the world's largest provider of private DNA tests, Mr. Vitulli served as President and CEO of Sciona, Inc., a pioneering Personal Genetics company offering customized health and wellness solutions and as President and CEO for Amerifit Nutrition, Inc., a nutritional supplement company focused on women's health. Earlier in his career, Mr. Vitulli managed start-up enterprises for various investor groups and was a general manager of the $1 billion North American Gatorade business for the former Quaker Oats Company. He holds an MBA from New York University's Leonard N. Stern School of Business and a BA from College of the Holy Cross in Boston.
Perseon Corporation invests its resources in fighting humanity's worst disease: cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Tricia Ross Financial Profiles 310-622-8226 firstname.lastname@example.org